BioLargo Inc. Q2 2025 Revenues Drop to $2.78M Amid Decreased Pooph Sales; Engineering Segment Revenue Soars by 517%

BioLargo, Inc. (OTCQX:BLGO) has released its operating and financial results for the second quarter and first half of 2025. The company reported Q2 2025 revenues of $2.777 million and first-half 2025 revenues of $6.046 million. These figures reflect a decrease in sales volume of Pooph, BioLargo's pet odor product, private labeled to a third party. The company's engineering segment experienced a substantial increase in revenue, driven by new contracts to provide air quality control compliance services, resulting in a 517% rise in this sector. Additionally, Clyra Medical Technologies, a subsidiary of BioLargo, has secured multiple sales and distribution agreements, expanding its market reach to 6,100 hospitals, 6,300 ambulatory surgery centers, and 2,200 specialty wound care clinics in the U.S. BioLargo's Cellinity battery technology has shown promising results, as confirmed by an independent evaluation conducted by U.S. BESS Corporation, a leading energy storage solutions provider. The Cellinity technology has also attracted interest, leading to the signing of four memoranda of understanding with potential joint venture partners for the construction and operation of battery factories. Financially, BioLargo reported stockholders' equity of $6.060 million, total assets of $12.499 million, liabilities of $6.439 million, and cash and cash equivalents amounting to $3.471 million as of June 30, 2025. The company continues to work with Garratt Callahan to develop technologies for cooling tower water reuse, particularly targeting data centers. BioLargo's engineering and environmental services division is actively engaging with clients on significant projects, focusing on scope of work and budgeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1060439) on August 13, 2025, and is solely responsible for the information contained therein.